EUVIMEDEUVIMED entdecken
KommentarMetaanalyseOpen Access · CC BY 4.0

Commentary: Safety and efficacy of remimazolam versus propofol sedation in gynecological procedures: a meta-analysis of East Asian randomized trials

Munder Lateiresh

Frontiers in Medicine · 16.06.2026 · 13

DOI: 10.3389/fmed.2026.1821680 ↗

Kurz gefasst

Kommentar in der Zeitschrift Frontiers in Medicine, online erschienen am 16.06.2026. Verfasst von Munder Lateiresh. Beteiligte Einrichtung: Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We thank the reviewer for highlighting this important point. In the revised manuscript, we have reinstated and clarified the statement regarding the handling of multi-arm trials and shared control groups. Specifically, we now explicitly state that the original meta-analysis did not report whether a correction for potential double-counting of shared control groups was applied. We further clarify that this lack of reporting limits definitive conclusions regarding variance handling, and we emphasize the importance of transparent methodological reporting in multi-arm trial synthesis. This revision ensures consistency between the manuscript and the rebuttal letter.This has been corrected in the revised manuscript as suggested by the reviewer, with appropriate restructuring of the sentence.The sentence "Jin et al. [1] consider issuing a corrigendum..." has been corrected to remove the misplaced period.We have attempted to adjust and correct the reference formatting; however, the current output appears to be controlled by the EndNote style settings used for reference management, which automatically generate this format. We have verified the citation against the official Cochrane Handbook source and confirm its accuracy. We kindly hope that the journal production team may further standardize the formatting according to the journal's reference style during copy-editing if needed.Once again, we thank you for your thoughtful review and constructive suggestions. We believe that these revisions have strengthened our manuscript, and we look forward to your feedback.Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina munder.lateiresh2000@gmail.com short' one, with a context-sensitive half-time typically ranging from 3 to 10 minutes, comparable to other short-acting agents . Furthermore, to provide a more comprehensive context to the available literature on remimazolam, we refer readers to a recent narrative literature review on its use in cardiac and noncardiac surgery [3]. Here, 'trial-level heterogeneity' refers to variability in study designs, patient populations, and intervention protocols across the included trials, which may influence the overall treatment effect and the generalizability of the pooled findings.In their meta-analysis, Jin et al. [1] aimed to synthesize evidence on the safety and efficacy of remimazolam versus propofol. However, discrepancies in data extraction and outcome definition harmonization were observed, particularly concerning the study by Tan et al. [4]. Specifically, regarding hypotension, Tan et al. [4] reported a significantly lower incidence of hypotension in the remimazolam-propofol combination group (7.2%) compared with the propofol group (20.0%).However, this study was not included in the meta-analysis for hypotension (Figure 3a in Jin et al. [1]), which is a critical omission given its findings. Furthermore, Figure 3a in Jin et al. [1] reports 12 and 2 events for hypotension, but the source and context of these specific numeric events from other included studies are not explicitly detailed. This lack of clarity, coupled with the omission of relevant data from Tan et al. [4], limits the interpretability and comparability of the pooled estimate for hypotension.. Although hypotension data from Tan et al. [4] were presented in Table 2 of the meta-analysis [1],However, the methods used to define, extract, and harmonize hypotension outcomes across studies are not described in sufficient detail, particularly regarding consistency of hypotension thresholds and time windows. This limits interpretability and comparability of the pooled estimate. This highlights the importance of transparent and standardized outcome definitions and comprehensive data inclusion in safety meta-analyses.in safety meta-analyses.Regarding oxygen desaturation events, Tan et al. [4] reported 12 cases of SpO₂

Schlagwörter

Stichwörter der Autor:innen

anesthesiaanesthesia managementgynecologypropofolremimazolam

Autor:innen und Institutionen

  • Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina.

Zitieren

APA

Lateiresh, M. (2026). Commentary: Safety and efficacy of remimazolam versus propofol sedation in gynecological procedures: a meta-analysis of East Asian randomized trials. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1821680

Vancouver

Lateiresh M. Commentary: Safety and efficacy of remimazolam versus propofol sedation in gynecological procedures: a meta-analysis of East Asian randomized trials. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1821680

BibTeX
@article{Lateiresh2026,
  author = {Lateiresh, Munder},
  title = {Commentary: Safety and efficacy of remimazolam versus propofol sedation in gynecological procedures: a meta-analysis of East Asian randomized trials},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1821680}
}
Kostenlos starten →